10. July 2016

A cationic nanocrystal formulation containing dexamethasone acetate nanocrystals (0.05%) and polymyxin B (0.10%) for ophthalmic application was produced using a self-developed small scale method for wet bead milling. The formulation developed offers the advantage of increased saturation solubility of the drug (due to the nano-size of the crystals), increased residence time in the eye (due to small size and increased mucoadhesion by the cationic charge) resulting ultimately in potential...